Advertisement

Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

While cutting-edge therapies grace headlines, the impact of breakthrough research remains limited due to patient access, affordability, and adherence. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Alice L. Pomponio
Managing director, BrightEdge; Vice president, Innovation and Impact Investing, American Cancer Society
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
Advertisement
Advertisement